CYFRA 21-1 serum analysis in patients with esophageal cancer

Citation
Jg. Brockmann et al., CYFRA 21-1 serum analysis in patients with esophageal cancer, CLIN CANC R, 6(11), 2000, pp. 4249-4252
Citations number
15
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
10780432 → ACNP
Volume
6
Issue
11
Year of publication
2000
Pages
4249 - 4252
Database
ISI
SICI code
1078-0432(200011)6:11<4249:C2SAIP>2.0.ZU;2-A
Abstract
This study was conducted to determine a potential use of CYFRA 21-1 in pati ents suffering from carcinoma of the esophagus. CYFRA 21-1 serum concentrat ions of 50 patients with histologically proven malignant lesion of the esop hagus were compared with 50 healthy persons, 50 patients with benign esopha geal disease, and 50 patients with benign Lung disease, Additional analysis of serum carcinoembryonic antigen, CA 72-4, and squamous cell carcinoma-an tigen serum concentrations were performed. The patients with esophageal car cinoma underwent follow-up tumor marker examinations every three months for 1 gear, Analysis to detect statistically significant differences was condu cted to estimate a cutoff and to evaluate tumor entity, tumor stage, surviv al, and tumor-free survival. CYFRA 21-1 at a cutoff of 1.40 ng/ml showed an overall sensitivity to esoph ageal carcinoma of 36% (45.5% to squamous cell carcinoma, 17.6% to adenocar cinoma) at a specificity of 97.3%, CYFRA 21-1 concentrations showed a tende ncy to higher serum levels depending on local tumor burden. A correlation o f CYFRA 21-1 with various N- or M-stage disease was not observed. Postopera tive development in terms of survival and tumor-free survival showed signif icant correlation to preoperative CYFRA 21-1 concentrations. Clinical tumor recurrence was preceded by CYFRA 21-1 elevation by 3.4 months, For prognos is and followup, this marker is justified for additional analysis in a larg er series of patients suffering from carcinoma of the esophagus.